IL10 and neoplasm: HOCl: pilot study in five recurrent ovarian cancer patients demonstrated potent T cell responses against tumor antigens, decreased circulating Treg levels, and serum IL-10 levels and two patients experienced durable PFS responses of ≥24 months (14)